These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2004-004952-38 Randomised phase II trial of hyperbaric oxygen therapy in patients with chronic arm lymphoedema after radiotherapy for early breast cancer (HOT) 2008-12-31 due-trials
Reported results Terminated 2005-005721-55 Adjuvant Cytotoxic Chemotherapy in Older Women 2008-11-24 due-trials
Completed, report not yet due 2006-000687-89 A randomised phase III placebo-controlled trial evaluating the addition of celecoxib to standard treatment of transitional cell carcinoma of the bladder 2020-11-02 not-yet-due
Exempt Terminated 2006-001031-22 The Potentiation of Efficacy of Radiotherapy in Non-Small-Cell Lung Cancer (NSCLC) by Inhibition of Akt Activation 2011-03-29 not-yet-due
Other 2006-004470-26 Triple Negative breast cancer Trial. A randomised phase III trial of carboplatin compared to docetaxel for patients with metastatic or recurrent locally advanced ER-, PR- and HER2- breast cancer not-yet-due
Other 2007-003877-21 Trial of Perioperative Endocrine Therapy - Individualising Care (POETIC) not-yet-due
Reported results 2008-000707-28 A Phase II Trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic carcinoma of the penis 2017-09-27 due-trials
Other 2008-005466-30 Effect of Perioperative AntiHER2 Therapy on Early Breast Cancer Study - Biological Phase not-yet-due
Other 2008-006295-29 A single group trial evaluating one cycle of adjuvant BEP chemotherapy in high risk, stage 1 non-seminomatous germ cell tumours of the testis (NSGCTT) not-yet-due
Reported results 2009-012945-49 A Phase II Trial of Nilotinib in the Treatment of Patients with c-KIT Mutated Advanced Acral and Mucosal Melanoma (NICAM) 2016-12-12 due-trials
Other 2010-021163-33 A Phase II Trial of Cediranib in the Treatment of Patients with Alveolar Soft Part Sarcoma (CASPS) Ensayo fase II de Cediranib en el tratamiento de pacientes con sarcoma de partes blandas alveolar ... not-yet-due
Other 2011-000601-49 TOPARP: Phase II Trial of Olaparib in Patients with Advanced Castration Resistant Prostate Cancer. not-yet-due
Other 2011-002577-33 A Phase III randomised trial of Peri-Operative chemotherapy versus sUrveillance in upper Tract urothelial cancer not-yet-due
Other 2011-004562-16 A Phase II Study of Axitinib in Patients with Metastatic Renal Cell Cancer Unsuitable for Nephrectomy not-yet-due
Reported results 2012-002592-34 A Phase II Trial of Vinflunine chemotherapy in locally advanced and metastatic carcinoma of the penis 2018-11-06 due-trials
Exempt, with results 2012-003896-20 TAX-TORC: A Phase I multi-centre trial of the combination of AZD2014 (dual TORC1 and TORC2 inhibitor) and weekly paclitaxel in patients with solid tumours 2017-11-15 not-yet-due
Other 2013-000293-29 A prospective, multi-centre, open label, non-randomised two stage phase II clinical trial evaluating the efficacy of abiraterone in patients with epithelial ovarian (including fallopian tube and prima... not-yet-due
Other 2013-004055-20 A phase II randomised trial of biomarkers to assess (dose-) response in patients with metastatic castration resistant prostate cancer treated with radium-223. not-yet-due
Exempt 2013-004091-34 A randomised Phase II study of Enzalutamide (MDV3100) in combination with AZD5363 in Patients with Metastatic Castration - Resistant Prostate Cancer not-yet-due
Other 2013-005095-18 A phase II randomised feasibility study of chemoresection and surgical management in low risk non muscle invasive bladder cancer. not-yet-due
Reported results 2014-000887-16 A phase II randomised study evaluating the biological and clinical effects of the combination of palbociclib with letrozole as neoadjuvant therapy in post-menopausal women with ER+ primary breast canc... 2020-03-03 due-trials
Reported results 2014-003319-12 Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO) 2019-04-23 due-trials
Other 2015-001199-23 InPACT - International Penile Advanced Cancer Trial (International Rare Cancer Initiative) not-yet-due
Reported results Terminated 2015-001361-27 CTC-STOP: Utilising Circulating Tumour Cell (CTC) Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer. 2020-04-09 due-trials
Exempt, with results 2016-000833-40 Phase I ’run in’ study followed by randomised phase II trial testing intra-tumoural hydrogen peroxide as a radiation sensitizer in patients with locally advanced/recurrent breast cancer in terms of to... 2020-11-12 not-yet-due
Other 2016-000869-23 Targeting cancer care with the use of genetic profiling not-yet-due
Exempt 2016-003141-28 ACE: Proof of concept Phase I/II trial of the CXCR2 antagonist AZD5069, administered in combination with enzalutamide, in patients with metastatic castration resistant prostate cancer(mCRPC) not-yet-due
Other 2017-000508-92 c-TRAK TN: A clinical trial utilising ctDNA mutation tracking to detect minimal residual disease and trigger intervention in patients with moderate and high risk early stage triple negative breast can... not-yet-due
Other 2017-000931-15 PERSEUS1: Phase II Trial of the Immune Checkpoint Inhibitor Pembrolizumab For Patients Suffering from Metastatic Prostate Cancer. not-yet-due
Other 2018-002077-21 PHOENIX Trial: A pre-surgical window of opportunity and post-surgical adjuvant biomarker study of DNA damage response inhibition and/or anti-PD-L1 immunotherapy in patients with neoadjuvant chemothera... not-yet-due
Other 2018-003779-36 ATr inhibitor in combination with olaparib in gynaecological cancers with ARId1A loss or no loss not-yet-due
Other 2019-001709-25 Randomised phase II trial testing efficacy of intra-tumoural hydrogen peroxide as a radiation sensitiser in patients with locally advanced/recurrent breast cancer not-yet-due
Exempt 2019-003485-40 ACTION: Phase I/II Trial of Abiraterone Acetate in Combination with Tildrakizumab (anti-IL23 targeting monoclonal antibody) in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) not-yet-due
Other 2019-003897-24 PreOperative Endocrine Therapy for Individualised Care with Abemaciclib not-yet-due